GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mallinckrodt PLC (OTCPK:MCKPF) » Definitions » Shiller PE Ratio

Mallinckrodt (Mallinckrodt) Shiller PE Ratio : (As of May. 19, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Mallinckrodt Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mallinckrodt Shiller PE Ratio Historical Data

The historical data trend for Mallinckrodt's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mallinckrodt Shiller PE Ratio Chart

Mallinckrodt Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mallinckrodt Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mallinckrodt's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Mallinckrodt's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mallinckrodt's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mallinckrodt's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Mallinckrodt's Shiller PE Ratio falls into.



Mallinckrodt Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Mallinckrodt's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Mallinckrodt's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-3.32/120.9901*120.9901
=-3.320

Current CPI (Mar. 2024) = 120.9901.

Mallinckrodt Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 0.200 100.573 0.241
201406 -0.410 100.773 -0.492
201409 -4.140 100.474 -4.985
201412 0.790 99.576 0.960
201503 0.840 99.975 1.017
201506 0.490 100.573 0.589
201509 0.630 100.274 0.760
201512 1.820 99.676 2.209
201603 1.060 99.676 1.287
201606 1.820 101.072 2.179
201609 1.060 100.274 1.279
201612 -1.450 99.676 -1.760
201703 3.850 100.374 4.641
201706 0.640 100.673 0.769
201709 0.660 100.474 0.795
201712 17.410 100.075 21.049
201803 -0.210 100.573 -0.253
201806 0.190 101.072 0.227
201809 1.340 101.371 1.599
201812 -44.640 100.773 -53.596
201903 1.830 101.670 2.178
201906 0.080 102.168 0.095
201909 -0.010 102.268 -0.012
201912 -13.760 102.068 -16.311
202003 -0.600 102.367 -0.709
202006 -11.040 101.769 -13.125
202009 2.260 101.072 2.705
202012 -1.810 101.072 -2.167
202103 -1.700 102.367 -2.009
202106 -1.250 103.364 -1.463
202109 -3.110 104.859 -3.588
202112 -2.410 106.653 -2.734
202203 -1.410 109.245 -1.562
202206 -2.290 112.779 -2.457
202209 -26.410 113.504 -28.152
202212 -19.000 115.436 -19.914
202303 -18.930 117.609 -19.474
202306 -56.740 119.662 -57.370
202309 -128.600 120.749 -128.857
202403 -3.320 120.990 -3.320

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mallinckrodt  (OTCPK:MCKPF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Mallinckrodt Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Mallinckrodt's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mallinckrodt (Mallinckrodt) Business Description

Traded in Other Exchanges
N/A
Address
College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.
Executives
Alta Fundamental Advisers Llc 10 percent owner 1500 BROADWAY, SUITE 704, NEW YORK NY 10036
Jason Daniel Goodson officer: EVP & Head of Corp Development 106 CENTRAL PARK AVENUE, WENTZVILLE MO 63885
James R Sulat director
Paul Bisaro director
Sigurdur O Olafsson director, officer: President and CEO 360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960
Stephen Andrew Welch officer: EVP & Head of Spec Generics 18440 BRIDGEMORE LANE, LOUISVILLE KY 40245
Peter C Richardson officer: EVP & Chief Scientific Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Susan Michele Silbermann director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lisa French officer: EVP & Chief Commercial Officer 301 CONTINENTAL LANE, PAOLI PA 19301
Mark Anthony Tyndall officer: EVP & Chief Legal Offi & Secre 1101 Q ST NW, WASHINGTON DC 20009
Henriette Nielsen officer: EVP & Chief Transformation OFC 202 WEST 85TH STREET, APT. 5, NEW YORK NY 10024
Karen Ling director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Olifant Luxco S.a R.l. 10 percent owner 19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Paul Rutherford Carter director SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF

Mallinckrodt (Mallinckrodt) Headlines